Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Alzheimers Dement ; 13(9): 1013-1023, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28263741

RESUMO

INTRODUCTION: Hippocampal volume is a core biomarker of Alzheimer's disease (AD). However, its contribution over the standard diagnostic workup is unclear. METHODS: Three hundred fifty-six patients, under clinical evaluation for cognitive impairment, with suspected AD and Mini-Mental State Examination ≥20, were recruited across 17 European memory clinics. After the traditional diagnostic workup, diagnostic confidence of AD pathology (DCAD) was estimated by the physicians in charge. The latter were provided with the results of automated hippocampal volumetry in standardized format and DCAD was reassessed. RESULTS: An increment of one interquartile range in hippocampal volume was associated with a mean change of DCAD of -8.0% (95% credible interval: [-11.5, -5.0]). Automated hippocampal volumetry showed a statistically significant impact on DCAD beyond the contributions of neuropsychology, 18F-fluorodeoxyglucose positron emission tomography/single-photon emission computed tomography, and cerebrospinal fluid markers (-8.5, CrI: [-11.5, -5.6]; -14.1, CrI: [-19.3, -8.8]; -10.6, CrI: [-14.6, -6.1], respectively). DISCUSSION: There is a measurable effect of hippocampal volume on DCAD even when used on top of the traditional diagnostic workup.


Assuntos
Doença de Alzheimer/diagnóstico , Doença de Alzheimer/patologia , Transtornos Cognitivos/etiologia , Diagnóstico por Computador , Hipocampo/patologia , Doença de Alzheimer/líquido cefalorraquidiano , Doença de Alzheimer/complicações , Peptídeos beta-Amiloides/líquido cefalorraquidiano , Transtornos Cognitivos/diagnóstico por imagem , Diagnóstico Diferencial , Progressão da Doença , Europa (Continente) , Feminino , Fluordesoxiglucose F18/metabolismo , Humanos , Masculino , Testes Neuropsicológicos , Fragmentos de Peptídeos/líquido cefalorraquidiano , Tomografia por Emissão de Pósitrons , Tomografia Computadorizada de Emissão de Fóton Único , Proteínas tau/líquido cefalorraquidiano
2.
J Alzheimers Dis ; 56(2): 619-627, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28035922

RESUMO

BACKGROUND: It has been demonstrated that virtual reality (VR) applications can be used for the detection of mild cognitive impairment (MCI). OBJECTIVE: The aim of this study is to provide a preliminary investigation on whether a VR cognitive training application can be used to detect MCI in persons using the application at home without the help of an examiner. METHODS: Two groups, one of healthy older adults (n = 6) and one of MCI patients (n = 6) were recruited from Thessaloniki day centers for cognitive disorders and provided with a tablet PC with custom software enabling the self-administration of the Virtual Super Market (VSM) cognitive training exercise. The average performance (from 20 administrations of the exercise) of the two groups was compared and was also correlated with performance in established neuropsychological tests. RESULTS: Average performance in terms of duration to complete the given exercise differed significantly between healthy(µ  = 247.41 s/ sd = 89.006) and MCI (µ= 454.52 s/ sd = 177.604) groups, yielding a correct classification rate of 91.8% with a sensitivity and specificity of 94% and 89% respectively for MCI detection. Average performance also correlated significantly with performance in Functional Cognitive Assessment Scale (FUCAS), Test of Everyday Attention (TEA), and Rey Osterrieth Complex Figure test (ROCFT). DISCUSSION: The VR application exhibited very high accuracy in detecting MCI while all participants were able to operate the tablet and application on their own. Diagnostic accuracy was improved compared to a previous study using data from only one administration of the exercise. The results of the present study suggest that remote MCI detection through VR applications can be feasible.


Assuntos
Disfunção Cognitiva/diagnóstico , Diagnóstico por Computador , Telemedicina , Realidade Virtual , Idoso , Terapia Cognitivo-Comportamental , Computadores de Mão , Estudos de Viabilidade , Feminino , Humanos , Aprendizagem , Masculino , Pessoa de Meia-Idade , Aplicativos Móveis , Testes Neuropsicológicos , Sensibilidade e Especificidade , Fatores de Tempo
3.
J Alzheimers Dis ; 44(4): 1333-47, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25428251

RESUMO

BACKGROUND: Recent research advocates the potential of virtual reality (VR) applications in assessing cognitive functions highlighting the possibility of using a VR application for mild cognitive impairment (MCI) screening. OBJECTIVE: The aim of this study is to investigate whether a VR cognitive training application, the virtual supermarket (VSM), can be used as a screening tool for MCI. METHODS: Two groups, one of healthy older adults (n = 21) and one of MCI patients (n = 34), were recruited from day centers for cognitive disorders and administered the VSM and a neuropsychological test battery. The performance of the two groups in the VSM was compared and correlated with performance in established neuropsychological tests. At the same time, the effectiveness of a combination of traditional neuropsychological tests and the VSM was examined. RESULTS: VSM displayed a correct classification rate (CCR) of 87.30% when differentiating between MCI patients and healthy older adults, while it was unable to differentiate between MCI subtypes. At the same time, the VSM correlates with various established neuropsychological tests. A limited number of tests were able to improve the CCR of the VSM when combined with the VSM for screening purposes. DISCUSSION: VSM appears to be a valid method of screening for MCI in an older adult population though it cannot be used for MCI subtype assessment. VSM's concurrent validity is supported by the large number of correlations between the VSM and established tests. It is considered a robust test on its own as the inclusion of other tests failed to improve its CCR significantly.


Assuntos
Terapia Cognitivo-Comportamental/métodos , Disfunção Cognitiva/diagnóstico , Disfunção Cognitiva/reabilitação , Interface Usuário-Computador , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Estatística como Assunto , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA